Skip to main content

Advertisement

SpringerLink
Log in

Selective cyclooxygenase-2 inhibitor prevents reduction of trabecular bone mass in collagen-induced arthritic mice in association with suppression of RANKL/OPG ratio and IL-6 mRNA expression in synovial tissues but not in bone marrow cells

  • Original Article
  • Published:
Journal of Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

We performed this study to clarify whether celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, prevents trabecular bone mass reduction by suppressing arthritis-related increase of bone resorption, and to discriminate differences in actions on bone among celecoxib, SC-58560 (a selective COX-1 inhibitor), and indomethacin. Eight-week-old DBA/1J male mice were divided into six groups as follows. Control untreated (Normal) and collagen-induced arthritic (CIA) mice were compared with four treatment groups: celecoxib was orally administered to CIA mice at doses of 0 (Vehicle), 16 (COX2L), and 75 (COX2H) mg/kg, in addition to two groups of mice treated with SC-58560 (COX1) or indomethacin (IND). Histomorphometry showed a significant decrease in tibial trabecular bone volume in arthritic mice, which was corrected by COX2H. The increased osteoclast surface and number in the Vehicle group were suppressed by COX2L, COX2H, and IND. The decreased bone formation rate in Vehicle was elevated by COX2H without statistical significance. A high ratio of mRNA expression of receptor activator of NF-κB ligand (RANKL)/osteoprotegerin (OPG) in Vehicle synovial tissue was suppressed by COX2L and COX2H. The increased expression of interleukin (IL)-6 mRNA in Vehicle was suppressed by COX2L, COX2H, and IND, although no difference in this expression was observed in bone marrow cells among all groups. In conclusion, in CIA mice, celecoxib suppresses arthritis-related increase in bone resorption at low and high doses and prevents trabecular bone mass reduction at high doses in association with suppression of osteoclast development in bone marrow through inhibition of RANKL/OPG ratio and IL-6 mRNA expression in inflammatory synovial tissue.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Nishida S, Tsurukami H, Sakai A, Sakata T, Ikeda S, Tanaka M, Ito M, Nakamura T (2002) Stage-dependent change in trabecular bone turnover and osteogenic capacity of marrow cells during development of type II collagen-induced arthritis in mice. Bone (NY) 30:872–879

    CAS  Google Scholar 

  2. Raisz LG (1999) Prostaglandins and bone: physiology and pathophysiology. Osteoarthritis Cartilage 7:419–421

    Article  PubMed  CAS  Google Scholar 

  3. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS (2000) Gastrointestinal toxicity with celecoxib vs. nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 284: 1247–1255

    Article  PubMed  CAS  Google Scholar 

  4. Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D, Erdmann E, Laine L; MEDAL Steering Committee (2006) Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 368:1771–1781

    Article  PubMed  CAS  Google Scholar 

  5. Katagiri M, Ogasawara T, Hoshi K, Chikazu D, Kimoto A, Noguchi M, Sasamata M, Harada S, Akama H, Tazaki H, Chung UI, Takato T, Nakamura K, Kawaguchi H (2006) Suppression of adjuvantinduced arthritic bone destruction by cyclooxygenase-2 selective agents with and without inhibitory potency against carbonic anhydrase II. J Bone Miner Res 21:219–227

    Article  PubMed  CAS  Google Scholar 

  6. Danks L, Sabokbar A, Gundle R, Athanasou NA (2002) Synovial macrophage-osteoclast differentiation in inflammatory arthritis. Ann Rheum Dis 61:916–921

    Article  PubMed  CAS  Google Scholar 

  7. Takayanagi H, Ogasawara K, Hida S Chiba T, Murata S, Sato K, Takaoka A, Yokochi T, Oda H, Tanaka K, Nakamura K, Taniguchi T (2000) T-cell-mediated regulation of osteoclastogenesis by signaling cross-talk between RANKL and IFN-γ. Nature (Lond) 408:600–605

    Article  CAS  Google Scholar 

  8. Urushibara M, Takayanagi H, Koga T, Kim S, Isobe M, Morishita Y, Nakagawa T, Loeffler M, Kodama T, Kurosawa H, Taniguchi T (2004) The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-κB ligandstimulated induction of nuclear factor of activated T cells c1. Arthritis Rheum 50:794–804

    Article  PubMed  CAS  Google Scholar 

  9. Niki Y, Takaishi H, Takito J, Miyamoto T, Kosaki N, Matsumoto H, Toyama Y, Tada N (2007) Administration of cyclooxygenase-2 inhibitor reduces joint inflammation but exacerbates osteopenia in IL-1α transgenic mice due to GM-CSF overproduction. J Immunol 179:639–646

    PubMed  CAS  Google Scholar 

  10. Tsuboi H, Nampei A, Matsui Y, Hashimoto J, Kawai S, Ochi T, Yoshikawa H (2007) Celecoxib prevents juxta-articular osteopenia and growth plate destruction adjacent to inflamed joints in rats with collagen-induced arthritis. Mod Rheumatol 17:115–122

    Article  PubMed  CAS  Google Scholar 

  11. Sakai A, Nakamura T, Tsurukami H, Okazaki R, Nishida S, Tanaka Y, Norimura T, Suzuki K (1996) Bone marrow capacity for bone cells and trabecular bone turnover in immobilized after sciatic neurectomy in mice. Bone (NY) 18:479–486

    CAS  Google Scholar 

  12. Okazaki R, Sakai A, Ootsuyama A, Sakata T, Nakamura T, Norimura T (2003) Apoptosis and p53 expression in chondrocytes relate to degeneration in articular cartilage of immobilized knee joints. J Rheumatol 30:559–566

    PubMed  CAS  Google Scholar 

  13. Trentham DE, McCune WJ, Susman P, David JR (1980) Autoimmunity to collagen in adjuvant arthritis of rats. J Clin Invest 66:1109–1117

    PubMed  CAS  Google Scholar 

  14. Suzuki Y, Kim KJ, Kotake S, Itoh T (2001) Stromal cell activity in bone marrow from the tibia and iliac crest of patients with rheumatoid arthritis. J Bone Miner Metab 19:56–60

    Article  PubMed  CAS  Google Scholar 

  15. Suzuki Y, Nishikaku F, Nakatuka M, Koga Y (1998) Osteoclastlike cells in murine collagen induced arthritis. J Rheumatol 25:1154–1160

    PubMed  CAS  Google Scholar 

  16. Sakai A, Sakata T, Ikeda S, Uchida S, Okazaki R, Norimura T, Hori M, Nakamura T (1999) Intermittent administration of human parathyroid hormone(1–34) prevents immobilization-related bone loss by regulating bone marrow capacity for bone cells in ddY mice. J Bone Miner Res 14:1691–1699

    Article  PubMed  CAS  Google Scholar 

  17. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595–610

    PubMed  CAS  Google Scholar 

  18. Pitaru S, Kotev-Emeth S, Noff D, Kaffuler S, Savion N (1993) Effect of basic fibroblast growth factor on the growth and differentiation of adult stromal bone marrow cells: enhanced development of mineralized bone-like tissue in culture. J Bone Miner Res 8:919–929

    PubMed  CAS  Google Scholar 

  19. Takahashi N, Yamana H, Yoshiki S, Roodman GD, Mundy GR, Jones SJ, Boyde A, Suda T (1988) Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. Endocrinology 122:1373–1382

    Article  PubMed  CAS  Google Scholar 

  20. Yamanishi Y, Boyle DL, Pinkoski MJ, Mahboubi A, Lin T, Han Z, Zvaifler NJ, Green DR, Firestein GS (2002) Regulation of joint destruction and inflammation by p53 in collagen-induced arthritis. Am J Pathol 160:123–130

    PubMed  CAS  Google Scholar 

  21. Bajtner E, Nandakumar KS, Engstrom A, Holmdahl R (2005) Chronic development of collagen-induced arthritis is associated with arthritogenic antibodies against specific epitopes on type II collagen. Arthritis Res Ther 7:R1148–R1157

    Article  PubMed  CAS  Google Scholar 

  22. Schramm C, Kriegsmann J, Protschka M, Huber S, Hansen T, Schmitt E, Galle PR, Blessing M (2004) Susceptibility to collagen-induced arthritis is modulated by TGF-β responsiveness of T cells. Arthritis Res Ther 6:R114–R119

    Article  PubMed  CAS  Google Scholar 

  23. Aota S, Nakamura T, Suzuki K, Tanaka Y, Okazaki Y, Segawa Y, Miura M, Kikuchi S (1996) Effects of indomethacin administration on bone turnover and bone mass in adjuvant-induced arthritis in rats. Calcif Tissue Int 59:385–391

    Article  PubMed  CAS  Google Scholar 

  24. Igarashi K, Woo JT, Stern PH (2002) Effects of a selective cyclooxygenase-2 inhibitor, celecoxib, on bone resorption and osteoclastogenesis in vitro. Biochem Pharmacol 63:523–532

    Article  PubMed  CAS  Google Scholar 

  25. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20:345–357

    Article  PubMed  CAS  Google Scholar 

  26. Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy G (1986) Stimulation of bone resorption and inhibition of bone formation in vitro by human tumor necrosis factors. Nature (Lond) 319:516–518

    Article  CAS  Google Scholar 

  27. Hughes FJ, Howells GL (1993) Interleukin-6 inhibits bone formation in vitro. Bone Miner 21:21–28

    Article  PubMed  CAS  Google Scholar 

  28. Stashenko P, Dewhrist FE, Rooney ML, Dejardin LA, Heeley D (1987) Interleukin-1β is a potent inhibitor of bone formation in vitro. J Bone Miner Res 2:559–565

    Article  PubMed  CAS  Google Scholar 

  29. Nguyen L, Dewhrist FE, Hauschka PV, Stashenko P (1991) Interleukin-1β stimulates bone resorption and inhibits bone formation in vivo. Lymphokine Cytokine Res 10:15–21

    PubMed  CAS  Google Scholar 

  30. Nakai K, Tanaka S, Sakai A, Nagashima M, Tanaka M, Otomo H, Nakamura T (2006) Cyclooxygenase-2 selective inhibition suppresses restoration of tibial trabecular bone formation in association with restriction of osteoblast maturation in skeletal reloading after hindlimb elevation of mice. Bone (NY) 39:83–92

    CAS  Google Scholar 

  31. Goodman S, Ma T, Trindade M, Ikenoue T, Matsuura I, Wong N, Fox N, Genovese M, Regula D, Smith RL (2002) COX-2 selective NSAID decreases bone ingrowth in vivo. J Orthop Res 20: 1164–1169

    Article  PubMed  CAS  Google Scholar 

  32. Sugiyama T (2001) Involvement of interleukin-6 and prostaglandin E2 in periarticular osteoporosis of postmenopausal women with rheumatoid arthritis. J Bone Miner Metab 19:89–96

    Article  PubMed  CAS  Google Scholar 

  33. Wittenberg RH, Willburger RE, Kleemeyer KS, Peskar BA (1993) In vitro release of prostaglandins and leukotrienes from synovial tissue, cartilage, and bone in degenerative joint diseases. Arthritis Rheum 36:1444–1450

    Article  PubMed  CAS  Google Scholar 

  34. Wong PK, Quinn JM, Sims NA, van Nieuwenhuijze A, Campbell IK, Wicks IP (2006) Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum 54:158–168

    Article  PubMed  CAS  Google Scholar 

  35. Kishimoto Y, Fukumoto S, Nishihara S, Mizumura H, Hirai K, Teshima R (2004) Gene expression relevant to osteoclastogenesis in the synovium and bone marrow of mature rats with collagen-induced arthritis. Rheumatology (Oxf) 43:1496–1503

    Article  CAS  Google Scholar 

  36. Yamamura Y, Gupta R, Morita Y, He X, Pai R, Endres J, Freiberg A, Chung K, Fox DA (2001) Effector function of resting T cells: activation of synovial fibroblasts. J Immunol 166: 2270–2275

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Orthopaedic Surgery, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8555, Japan

    Tomonori Taketa, Akinori Sakai, Shinya Tanaka, Kenichiro Nakai, Kunitaka Menuki, Hirotoshi Yamane, Kazuhiro Tanaka & Toshitaka Nakamura

Authors
  1. Tomonori Taketa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Akinori Sakai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shinya Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kenichiro Nakai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kunitaka Menuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hirotoshi Yamane
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kazuhiro Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Toshitaka Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Akinori Sakai.

About this article

Cite this article

Taketa, T., Sakai, A., Tanaka, S. et al. Selective cyclooxygenase-2 inhibitor prevents reduction of trabecular bone mass in collagen-induced arthritic mice in association with suppression of RANKL/OPG ratio and IL-6 mRNA expression in synovial tissues but not in bone marrow cells. J Bone Miner Metab 26, 143–151 (2008). https://doi.org/10.1007/s00774-007-0808-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00774-007-0808-2

Key words

Search

Navigation